We have analysed the frequency, severity and impact on virological outcomes of ALT flares in the so far largest, international, multicentre clinical trial investigating PEG‐IFNa‐2a treatment in hepatitis D patients—the HIDIT‐II clinical trial [16]. The gene discussed is GPT; the disease is hepatitis D virus infection.